- Home
- EHTH vs IKT Comparison
EHTH vs IKT Comparison
Compare EHTH & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHTH
- IKT
- Stock Information
- Founded
- EHTH 1997
- IKT 2008
- Country
- EHTH United States
- IKT United States
- Employees
- EHTH N/A
- IKT N/A
- Industry
- EHTH Specialty Insurers
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- EHTH Finance
- IKT Health Care
- Exchange
- EHTH Nasdaq
- IKT Nasdaq
- Market Cap
- EHTH 153.5M
- IKT 159.2M
- IPO Year
- EHTH 2006
- IKT 2020
- Fundamental
- Price
- EHTH $4.78
- IKT $2.05
- Analyst Decision
- EHTH Buy
- IKT Strong Buy
- Analyst Count
- EHTH 3
- IKT 2
- Target Price
- EHTH $7.33
- IKT $6.50
- AVG Volume (30 Days)
- EHTH 214.4K
- IKT 359.9K
- Earning Date
- EHTH 11-06-2024
- IKT 11-14-2024
- Dividend Yield
- EHTH N/A
- IKT N/A
- EPS Growth
- EHTH N/A
- IKT N/A
- EPS
- EHTH N/A
- IKT N/A
- Revenue
- EHTH $464,891,000.00
- IKT $1.00
- Revenue This Year
- EHTH $9.22
- IKT N/A
- Revenue Next Year
- EHTH $6.32
- IKT N/A
- P/E Ratio
- EHTH N/A
- IKT N/A
- Revenue Growth
- EHTH 15.78
- IKT N/A
- 52 Week Low
- EHTH $3.58
- IKT $0.80
- 52 Week High
- EHTH $9.45
- IKT $3.82
- Technical
- Relative Strength Index (RSI)
- EHTH 46.70
- IKT 42.19
- Support Level
- EHTH $5.14
- IKT $2.56
- Resistance Level
- EHTH $5.42
- IKT $3.69
- Average True Range (ATR)
- EHTH 0.32
- IKT 0.34
- MACD
- EHTH -0.06
- IKT -0.10
- Stochastic Oscillator
- EHTH 43.06
- IKT 5.75
About EHTH eHealth Inc.
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare and Employer and Individual. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.